

12 July 2024

China Resources Pharmaceutical Group Limited

41/F, China Resources Building 26 Harbour Road Wanchai Hong Kong Attn.: The Board of Directors

Dear Sirs,

Company	:	China Resources Pharmaceutical Group Limited ("Company", together with its subsidiaries, the "Group") (Stock Code: 3320)
Subject	:	CONTINUING CONNECTED TRANSACTIONS SALES FRAMEWORK AGREEMENT REVISION OF ANNUAL CAPS AND EXTENSION OF TERM

We refer to the circular of the Company dated 12 July 2024 (the "**Circular**") in relation to the captioned subject. Unless the context otherwise requires, terms used herein shall have the same meaning as those in the Circular.

We hereby confirm that we have given, and have not withdrawn, our written consent to the issue of the Circular with the inclusion therein of our advice letter dated 12 July 2024 and/or reference to our name and/or advice letter (as the case may be) in the form and context in which they respectively appear in the Circular.

We also confirm that as at the Latest Practicable Date, we (i) did not have any shareholding in the Group or any right (whether legally enforceable or not) to subscribe for or to nominate persons to subscribe for securities in the Group; and (ii) did not have any interest, either directly or indirectly, in any assets which have been, since 31 December 2023 (being the date to which the latest published audited accounts of the Company were made up), acquired or disposed of by or leased to the Company, or were proposed to be acquired or disposed of by or leased to the Company.

We hereby further consent to this letter and our letter as set out in "LETTER FROM THE INDEPENDENT FINANCIAL ADVISER" of the Circular being made available on display for inspection, if applicable, during the period and at the relevant websites as set out in the paragraph headed "9. DOCUMENTS ON DISPLAY" in Appendix I to the Circular.

Yours faithfully, For and on behalf of **China Sunrise Capital Limited**

Name: Cecilia Tam Title: Executive Director